Document is current

Article History

Received: 2 May 2025

Accepted: 25 June 2025

First Online: 11 July 2025

Declarations

:

: David T. Rubin, Grant support: Takeda; Consultant: Abbvie, Abivax SA, Altrubio, Avalo Therapeutics, Bausch Health, Bristol-Myers Squibb, Buhlmann Diagnostics Corp, Celltrion, ClostraBio, Connect BioPharma, Douglas Pharmaceuticals, Eli Lilly & Co., Foresee, Genentech (Roche) Inc., Image Analysis Group, InDex Pharmaceuticals, Iterative Health, Janssen Pharmaceuticals, Odyssey Therapeutics, Pfizer, Sanofi, Takeda Pharmaceuticals, Throne, Vedanta. Serves on the Board of Trustees for the Crohn’s & Colitis Foundation and is on the Board of Directors for Cornerstones Health. Simon Travis, Consulting fees: Abbvie, Apexian, BMS, BMS, Buhlmann; Bioclinica ChemoCentryx, Cosmo; Endpoint Health, Enterome, Equilibrium, Ferring; Genentech/Roche; GSK; Immunocore, Immunometabolism, Janssen, Lilly, Mestag, Novartis, Pfizer, Roche, Sensyne, Sanofi, Satisfai, Spyre, Takeda, Tr1X Bio, UCB Pharma, VHsquared, Vifor, Protagonist; Grants: Abbvie, IOIBD, Eli Lilly and Company, UCB, Vifor, Norman Collisson Foundation, Pfizer, UKEIRI, ECCO, Helmsley Trust, GSK; Honoraria: Ferring, Takeda, Eli Lilly and Company, BMS, Janssen, Violicom, Sun Pharma; Employment: University of Oxford; Royalties: Oxford University Press; Stockholder: Satisfai Health Inc; Travel: Abbvie, Eli Lilly and Company, Janssen, Pfizer, Takeda, Ferring, Amgen, Biogen, Sun Pharma. Marla C. Dubinsky, Consultant and Advisor: Abbvie, Abivax, Astra Zeneca, BMS, Celltrion, Eli Lilly, Janssen, Johnson and Johnson, Merck, Pfizer, Prometheus Labs, Sanofi, Spyre, Takeda. Stefan Schreiber, Personal fees from Abbvie, Amgen, Arena, Biogen, Bristol-Meyers Squibb, Celgene, Celltrion, Falk, Ferring, Fresenius Kabi, Galapagos, Gilead, IMAB, Janssen, Lilly, Morphic, MSD, Mylan, Novartis, Pfizer, Protagonist, Provention Bio, Roche, Sandoz/Hexal, Shire, Takeda, Theravance, and Ventyx. Remo Panaccione, Consultant: Abbott, AbbVie, Abbivax, Alimentiv (formerly Robarts), Amgen, AnaptysBio, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Spyre Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Union Biopharma, Viatris, Ventyx, UCB; Speaker: AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Gilead Sciences, Janssen, Merck, Organon, Pfizer, Roche, Sandoz, Shire, Takeda Pharmaceuticals; Advisory Board member: AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, SandozShire, Sublimity Therapeutics, Takeda Pharmaceuticals, Ventyx. Christian Atkinson, Employment: Adelphi Real World. Toshifumi Hibi, Personal fees: Abbvie GK, EA Pharma, Mitsubishi-Tanabe, Takeda Pharmaceutical, Pfizer, Celltrion, Eli Lilly, Gilead Sciences; Grants and personal fees: JIMRO, Mochida Pharmaceutical, Zeria Pharmaceutical, Miyarisan; Grants: Kyorin, Alfresa Pharma. Alison Potts Bleakman, Angelo D. Favia, Cem Kayhan, Eoin Flynn, Sonal Saxena, Theresa Hunter Gibble, and Tommaso Panni are employees and shareholders of Eli Lilly and Company.

: All participants provided informed consent to participate in the study via an IRB-approved informed consent form. The protocol and supporting data collection materials were approved by the Western Institutional Review Board (study number: 1307697). The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was consistent with Good Pharmacoepidemiology Practices and applicable laws and regulations of the countries where the study was conducted. Patients and HCPs were paid a nominal honorarium for completing the surveys.